Background. Preoperative portal vein occlusion with either percutaneous portal vein embolization (PVE) or portal vein ligation is routinely used to induce liver hypertrophy prior to major liver resection in patients with hepatic malignancy. While this increases the future liver remnant, and hence the number of patients suitable for resection, recent evidence suggests that induction of liver hypertrophy preoperatively may promote tumor growth and increase recurrence rates. The aims of this current study were to evaluate the impact of PVE on hepatic recurrence rate and survival in patients with colorectal liver metastases (CRLM). Methods. The MEDLINE, EMBASE and Web of Science databases were searched to identify studies assessing the oncological outcomes of patients undergoing major liver resection for CRLM following PVE. Studies comparing patients undergoing one-stage liver resection with or without preoperative PVE were included. The primary outcome was postoperative hepatic recurrence (PHR), while secondary outcomes were 3-and 5-year overall survival (OS). Results. Of the 2131 studies identified, six non-randomized studies (n = 668) met the eligibility criteria, comparing outcomes of patients undergoing major liver resection with or without PVE (n = 182 and n = 486, respectively Liver resection remains the only treatment offering both long-term survival 1-3 and potential cure 4 in patients with colorectal liver metastases (CRLM). The aim of surgery is to offer curative resection with preservation of a sufficient future liver remnant (FLR) 5 to minimize postoperative morbidity and mortality 6 . Unfortunately, at the time of diagnosis \25 % of patients are suitable for surgery, 7 with insufficient FLR being a principle limiting factor 8 . Portal vein occlusion (PVO) with either percutaneous portal vein embolization (PVE) or operative portal vein ligation (PVL) has been widely used to induce preoperative hypertrophy of the FLR in order to increase the resection rate [9] [10] [11] . Although PVE can increase the liver volume by, on average, 11.9 % 12 , recent studies have shown that it could also promote tumor growth [13] [14] [15] . Furthermore, the rate of tumor growth was more rapid than liver regeneration 15 . As a result, the impact of PVE on postoperative hepatic recurrence (PHR) and longterm oncological outcomes after resection of CLRM remains debatable, with some studies reporting a poor overall survival (OS) in the PVE group 15, 16 . Over the last 5 years, there has been increasing interest in surgical approaches to induce liver hypertrophy such as Associating Liver Partition and Portal vein ligation for Staged hepatectomy (ALPPS) 17 , Radio-frequency-Assisted Liver Partition with Portal vein ligation (RALPP) 18 and
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Associating Liver Tourniquet and right Portal occlusion for Staged hepatectomy technique (ALTPS) 19 . The advantages of these procedures over PVE are still being evaluated. The aim of this meta-analysis was to evaluate the impact of PVE on hepatic recurrence and survival following major liver resection in patients with CRLM.
METHODS

Search Strategy
A systematic literature search of the MEDLINE, EMBASE and Web of Science databases was carried out, using the following search terms: 'portal', 'embolization', 'embolisation', 'occlusion', 'ligation', 'metasta*' (the table in Supplemental Digital Content 1 contains the full electronic search strategy for MEDLINE), with no language or publication status restrictions. Searches were cross-referenced and extended on MEDLINE using the related articles function. We also searched for relevant publications of 'expert' authors (known to have published in the field of PVE and CRLM). The reference list of retrieved articles was also used to identify additional eligible studies. The first search was carried out on 15 March 2015, and the last search was undertaken on 10 October 2015.
Study Selection
To be eligible for the analysis, studies had to (i) include patients over 18 years of age undergoing one-stage liver resection for CRLMs with curative intent; (ii) compare patients undergoing major liver resection with preoperative PVE (PVE group) with those not undergoing preoperative PVE (no PVE group); (iii) report the rate of hepatic recurrence in both groups; and (iv) follow-up patients for hepatic recurrence for at least 12 months. Definition of major liver resection includes (i) left or right hepatectomy; (ii) right trisegmentectomy; and (iii) right or left extended hepatectomy. Studies were excluded if they were (i) review articles, case reports, laboratory studies or letters; (ii) unpublished data from meeting abstracts; or (iii) lacked essential information for the calculation of outcomes. Two reviewers (MCG and AG) independently assessed the retrieved references at title and abstract level to identify potential eligible studies. Any conflict was resolved by a third reviewer (AD) until a consensus was reached. The full-text of these studies was then retrieved for further analysis.
Data Extraction, Quality and Risk of Bias Assessment
Two authors independently extracted or calculated relevant data from each included study by completing an electronic database with the following information: first author, year of publication, country of origin, indication for PVE, time between PVE and surgery, duration of followup, characteristics of patients (see the table in Supplemental Digital Content 2), rate of hepatic recurrence, and 3-and 5-year OS. When the rates of OS at 3 and 5 years were not available in the text, these were retrieved by analysis of the published Kaplan-Meier survival curves using the method proposed by Tierney et al. 20 To obtain information on administration of interval chemotherapy between PVE and surgery, three corresponding authors were contacted, of whom one kindly replied (see the table in Supplemental Digital Content 2).
The Newcastle-Ottawa Scale (NOS) 22 was used to appraise the quality of the included studies. This tool assesses the risk of bias in three domains: Comparability of patients, Selection of patients and evaluation of the Outcome. We used the NOS to appraise the last two domains and evaluated the former with a tailored assessment, thus being able to consider the comparability of the two groups for more than the two factors allowed by the NOS. We achieved this as follows. Patients requiring PVE before surgery usually have a higher tumor burden than patients not requiring PVE and, consequently, the first group may be at higher risk of recurrence (baseline Rec RISK ) independently from the embolization. Thus, we considered if the groups (PVE and no PVE) were comparable for factors known to influence the risk of hepatic recurrence after resection of CRLM 23 : type (synchronous vs. metachronous), number, size, distribution (unilobar vs. bilobar) of metastases, perioperative chemotherapy, rate of R0 resections, and stage of primary tumor. Publication bias was assessed by graphical exploration using funnel plots of study results against precision of the study. Symmetry of the funnel plots was also tested using the Peters' and Harbord's modified tests, which are both regression tests between the effect estimates and their standard errors.
Outcome Analysis
The primary outcome of this meta-analysis was PHR, while secondary outcomes were 3-and 5-year OS. Odds ratios (ORs) and 95 % confidence intervals (CIs) were used as summary measures. The point estimate of the OR was considered statistically significant at p \ 0.05 if the 95 % CI did not include 1. They were calculated with the fixedeffects Mantel-Haenzel model, unless there was significant heterogeneity across studies, in which case the randomeffects DerSimonian and Laird model was used. Heterogeneity among studies was tested using the Q statistic and quantified using the I 2 statistic 24 . As a guide, I 2 values \25 % indicate low heterogeneity, 25-50 % indicate moderate heterogeneity, and values [50 % indicate high heterogeneity. For dichotomous analyses with zero-count cells, 0.5 was added to each cell for the analysis. The influence of each individual study included in the metaanalysis was investigated by omitting each study in turn and re-estimating the summary effect. When a fixed-effects model was used on the first, the analysis was repeated using a random-effect model. Statistical analyses were performed using STATA 12 statistical software (STATA Corp, College Station, TX, USA). The study was reported in accordance with the Meta-analysis Of Observational Studies in Epidemiology (MOOSE) guidelines for reporting meta-analysis of observational studies. 25 
RESULTS
Study Selection
The literature search identified a total of 3322 studies, of which 1191 were found to be duplicates and were removed. Of the 2131 remaining studies, 2104 were discarded because they failed to meet the inclusion criteria. The full text of the remaining 27 articles was examined in more detail, with six studies being included in the meta-analysis (Fig. 1) . 8, 14, 16, 21, 26, 27 Study Characteristics
The included studies consisted of 668 patients undergoing liver resection for CRLM with preoperative PVE (n = 182) and without preoperative PVE (n = 486) (see the table in Supplemental Digital Content 2). In all studies, PVE was the chosen method for induction of liver hypertrophy before major resection. However, in one study 8 , nine patients in the PVE group (28 %) eventually underwent PVL as the FLR was considered insufficient at the time of laparotomy. In two studies 16 ,26 a few patients had two-stage hepatectomy (n = 25 and 11, respectively). The mean time between PVE and surgery was 52.8 days, and the median follow-up time ranged from 23.5 to 46 months. Other characteristics of the included studies are shown in Table 1 .
Quality Assessment and Risk of Bias
Results of the quality assessment of the included studies and the risk of bias are shown in Table 2 . The NOS evaluation revealed no concerns about the selection of patients (all included studies reported 4/4), and the quality of outcome evaluation ranged between 2 and 3 (out of a maximum score of 3). The two groups of patients were comparable in terms of R0 resections and the use of perioperative chemotherapy in all the included studies. In three studies, 8, 14, 16 the PVE group had a higher baseline Rec RISK compared with the no PVE group, while the opposite occurred in one study 21 .
Outcomes Analyses
No difference in PHR was noted between patients in the PVE and no PVE groups (OR 0.78; 95 % CI 0.42-1.44; p = 0.41) (Fig. 2 ). OS at 3 years was similar between the two groups (OR 0.80; 95 % CI 0.56-1.14; p = 0.22) (Fig. 3a) , with no significant heterogeneity (Q 7.37; p = 0.19). At 5 years follow-up, no significant difference in survival remained (OR 1.12; 95 % CI 0.41-3.11; p = 0.82) (Fig. 3b ), but heterogeneity between the studies was detected (I 2 = 79.5 %; p = 0.001). The robustness of the results was confirmed by the influence analysis, which showed that results (PHR and OS) were not dependent on the inclusion of any study. Furthermore, this analysis identified the study by Oussoultzoglou et al. 21 as the source of the interstudy heterogeneity detected with regard to the PHR rate (I 2 = 54.2 %; Q 10.9; p = 0.05). In fact, after excluding this study, no significant heterogeneity remained (I 2 = 0 %; p = 0.79), or significant difference in PHR (OR 1; 95 % CI 0.68-1.47). No difference in PHR was found when this analysis was restricted to studies comparing patients undergoing right and extended right hepatectomy (OR 0.54; 95 % CI 0.13-2.30; p = 0.4). When a fixedeffects model was used on the first, analyses using a random-effects model confirmed the results (3-year OS: OR 0.9; 95 % CI 0.65-1.95). A funnel plot for the primary outcome showed symmetry (i.e. no publication bias) (see the figure in Supplemental Digital Content 3), which was confirmed using Peters' (p = 0.91) and Harbord's modified (p = 0.70) tests.
DISCUSSION
The effects of PVE on tumor growth in patients with CRLM have been previously reported, showing an increase in tumor volume in the embolized lobe 14 (20.8 % at 3 weeks) and also tumor growth rate. 28, 29 Similar findings have been reported in the non-embolized lobe 15 , with the growth rate of metastases having been shown to be more rapid than that of the regenerating liver parenchyma. 15 Different factors have been considered responsible for these changes. 29 As a consequence of portal flow reduction in the embolized lobe, arterial compensation occurs with decreased hepatic artery resistance 30 and increased arterial blood flow, 31 which could explain the progression of intrahepatic metastases whose blood supply is exclusively arterial. 32 As the tumor in the embolized lobe will be resected, these effects are not necessarily clinically relevant, unless this progression involves the hilum or the planned resection plane. 29 Conversely, in the non-embolized lobe, factors involved in liver regeneration may also stimulate tumor growth and the reactivation of dormant micrometastases 29, 33 to increase the risk of liver recurrence. The current study suggests that preoperative PVE does not adversely affect oncological outcomes after major liver resection in patients with CRLM. No difference in the incidence of PHR was found when comparing the PVE and no PVE groups. Although interstudy heterogeneity was detected, influence analysis identified the study by Oussoultzoglou et al. 21 as the source of this heterogeneity. Indeed, these authors found that PVE reduced PHR after right hepatectomy for CRLM; however, in this study, the PVE group had more patients with a single metastasis (Table 2) , than the no PVE group. Due to the small number of patients in the PVE group (n = 23), and the strong degree of correlation between presence of a single lesion and PVE, the multivariate analysis might not have been able to discriminate the independent contribution of these two variables to the reduced recurrence rate identified in this group. In our meta-analysis, after excluding this study and the result from the pooled analysis being more consistent, no difference in PHR remained.
Our analysis also showed no significant difference in 3-or 5-year OS between the two groups (Fig. 3) . These results are consistent with most of the evidence published in the literature. 8, 11, 21, 27, [34] [35] [36] [37] [38] Several studies have analyzed the effect of PVE on disease-free survival (DFS), with controversial results, showing both unaffected 21, 34 and compromised 14, 16, 26 DFS. In most of these studies, the DFS analyzed was not liver-specific, affected by colorectal recurrence at the site of the primary tumor, peritoneal and other extrahepatic sites. Ardito et al. 27 analyzed the liverspecific DFS curves for the two groups. At 5 years, no significant difference was observed, confirmed by multivariate analysis. However, the liver-specific DFS curves revealed that patients in the PVE group had experienced recurrence of CRLM much earlier than those without PVE. Pamecha et al. 26 reported that the median time to PHR was shorter in the PVE group compared with those not undergoing PVE (12 vs. 24 months). Hoekstra et al. 29 reported a significantly higher rate of PHR in the PVE group compared with those in the no PVE group (42 vs. 4 %) at the first postoperative scan at 3 months, although some argued that this finding might be due to lesions present at the time of resection. 29 These reports suggest that patients undergoing PVE may develop earlier PHR. Indeed, administration of perioperative chemotherapy is associated with improved DFS. 39, 40 In our included studies, the two groups were comparable for perioperative treatment (Table 2) ; however, this varied within each study, in terms of regimens, duration, and timing of administration (neoadjuvant or adjuvant). Although patient-tailored treatment might have contributed to this variation, it may also be because studies enrolled patients over a long time frame of 20 years (Table 1) , during which strategies of perioperative treatment have advanced. 41 Neoadjuvant chemotherapy was similarly administered in both groups NOTE: Weights are from random effects analysi s Overall (I−squared = 54.2%, p = 0.053) Pamecha et al. [26] Kokudo et al. [14] Oussoultzoglou et al [25] .
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There are some limitations to this meta-analysis. It is based on non-randomized studies as no randomized controlled trial has been conducted because it may be considered unethical. Consequently, an inherent risk of selection bias is present as patients requiring PVE before surgery usually have a higher tumor burden than patients not requiring PVE. As shown, we assessed this bias considering the comparability of the two groups of patients for many variables known to influence the risk of recurrence after resection. 23 Information about other variables (e.g. CEA, disease-free interval time) were not available for most of the studies and therefore we could not take them into account. The included studies exclusively reported survival data of patients who successfully underwent liver resection following PVE; therefore, an intention-to-treat survival analysis, including patients who remained unresectable after PVE, was precluded. This might also represent a selection bias. Indeed, patients reaching resection after PVE usually have a better response to neoadjuvant treatment compared with patients remaining unresectable after PVE because of disease progression. 8, 42 Response to preoperative treatment is reported to be associated with improved outcomes, 43 although some denied this finding. 44 In addition, disease progression following PVE is suggested to be due to aggressive tumor biology rather than an effect of PVE. 42 This suggests that patients reaching resection after PVE have favorable tumor biology. Indeed, it has already been emphasized that existence of this bias would lead us to find improved OS in PVE patients compared with the control group, 21 but this did not happen. In addition, two included studies, 16, 27 encompassing 60 % of patients, took into account response to neoadjuvant treatment (complete or partial, stable and progression). In both studies, the PVE and no PVE groups were fully comparable for type of response. Furthermore, no differences in PHR and OS were found between the groups. 16, 27 The small number of available studies limits the statistical power of this meta-analysis. Nevertheless, as can be seen by looking at the CIs in the forest plots, the statistical power of this analysis was greater than that of any individual study published so far. As such, this metaanalysis contributes additional new information to the literature. 45 Finally, in this meta-analysis, most of the patients requiring PVE underwent a one-stage procedure (80.3 %), which indicates a moderate tumor burden, with limited metastatic involvement of the FLR. The applicability of these results is therefore limited to this category of patients.
This meta-analysis also has several strengths. First, we performed a comprehensive literature review and reported the most up-to-date published data. Second, we described in detail the study characteristics, which has allowed us to put the results into clinical context and identify areas requiring further research.
CONCLUSIONS
The current literature review and pooled analyses suggest that preoperative PVE is not a risk factor for worse oncological outcomes in patients undergoing liver resection for CRLM. Further studies based on individual patient data are needed to overcome the abovementioned limitations, thus providing definitive answers and addressing pending interrogatives.
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